NewcelX Ltd. (NCEL) stock
NCELNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Last filing: 20-F on Apr 29, 2026Score 4/30
$2.54−0.15 (-5.58%)
Close on Nov 20, 2026Market cap $12.19MP/E 1.2Yield –
NewcelX r&d expenses
Research and development expenses are spending on new products and technology.
For fiscal 2025 it was $1.13M, up 13.5% from the year before. The highest annual figure on record is $8.98M in fiscal 2022.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.13M | +13.5% |
| FY2024 | Dec 31, 2024 | $992.00K | -38.3% |
| FY2023 | Dec 31, 2023 | $1.61M | -82.1% |
| FY2022 | Dec 31, 2022 | $8.98M | +51.6% |
| FY2021 | Dec 31, 2021 | $5.92M | +5844.4% |
| FY2020 | Dec 31, 2020 | $99.58K | -88.9% |
| FY2019 | Dec 31, 2019 | $897.79K | +26.7% |
| FY2018 | Dec 31, 2018 | $708.46K | – |
See a number that looks wrong?